Dividend-paying healthcare stocks? Now that’s a rare find—and it’s exactly why these two companies are turning heads. But here’s where it gets controversial: while the healthcare sector isn’t exactly known for generous dividends, Bristol Myers Squibb and Zoetis are breaking the mold with their recent raises. Let’s dive into what makes these companies stand out—and why they might just be worth your attention.
The holiday season is typically a quiet time for dividend hikes, but every now and then, a few companies surprise us by ending the year on a high note. This time around, two healthcare giants have done just that. And this is the part most people miss: these aren’t just any companies—they’re industry leaders with unique strengths that set them apart.
First up is Bristol Myers Squibb (BMY), a pharmaceutical powerhouse with a remarkable 94-year streak of paying dividends. That’s right—nearly a century of consistent payouts. But what’s even more impressive? They’ve raised their dividend for 17 consecutive years, with the latest increase announced in mid-December. Shareholders can now expect a quarterly payout of $0.63 per share, a 1.6% bump. Here’s the kicker: their dividend yield is nearly 5%, far outpacing most healthcare companies and many dividend-payers across industries.
What’s driving this success? Bristol Myers Squibb focuses on three key therapeutic areas: cardiovascular disease, immune disorders, and oncology. Their portfolio is split into 'growth' drugs—those with years of patent exclusivity left—and 'legacy' products nearing or past their patent expiration. The growth category, led by blockbuster cancer treatment Opdivo, has been the engine behind their recent revenue surge. In Q3 2025, growth drug sales jumped 18% year-over-year to $6.9 billion, offsetting a 12% decline in legacy revenue and pushing overall revenue up 3% to $12.2 billion.
Here’s a thought-provoking question: Can Bristol Myers Squibb sustain this growth as their legacy drugs face increasing competition? While their free cash flow (FCF) remains robust—over $5.9 billion in Q3—investors will be watching closely to see how they navigate the patent cliff.
Next, let’s talk about Zoetis (ZTS), a company that’s truly in a league of its own. Unlike Bristol Myers Squibb, Zoetis focuses exclusively on animal health—and it’s the largest player in this niche globally, with a 20% market share. Since spinning off from Pfizer in 2013, Zoetis has paid a dividend every quarter, and earlier this month, they raised their quarterly payout by 6% to $0.53 per share.
But here’s the controversial part: some investors argue that the animal health market is too small to sustain long-term growth. However, consider this: pet ownership in the U.S. has soared, with 66% of households owning a pet in 2023-2024, up from 56% in 1988. Zoetis capitalizes on this trend, with roughly two-thirds of its sales coming from pet medications. Meanwhile, global population growth is driving demand for animal protein, boosting their livestock business.
Zoetis’ financial performance speaks for itself. Over the past five years, annual revenue has climbed from $6.7 billion in 2020 to nearly $9.3 billion in 2024, while net income has risen from $1.6 billion to almost $2.5 billion. With a diverse pipeline and significant R&D investment, this company is poised for continued growth.
Here’s the big question for you: Are niche pharmaceutical companies like Zoetis the future of healthcare investing, or is their limited focus a risk? Let us know in the comments.
In summary, both Bristol Myers Squibb and Zoetis offer compelling dividend stories in a sector not known for them. Whether you’re drawn to the reliability of a century-old pharmaceutical giant or the growth potential of an animal health leader, these companies are worth a closer look. Bristol Myers Squibb’s next dividend will be paid on February 2, 2026, to shareholders of record on January 2, while Zoetis’ payout is set for March 3, 2026, with a record date of January 20. Yield estimates? 4.8% for Bristol Myers Squibb and 1.8% for Zoetis. Which one piques your interest more? Share your thoughts below!
